The acquisition will allow Ipca to re-enter US formulation generic market, however at 2.3x sales, as acquisition cost is expensive, given challenges and uncertainty associated with US market.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
